Scientific Reports · 2018 · 49 citations · 18 references
MedicineOncologyRadiologyOncologic Nuclear MedicineOral OncologySurgical OncologyNeck DissectionOral Cancer MetastasisOral Cavity CancerClinical Nodal StagingLymph Node Metastasis AssessmentLymph Node Metastasis PrognosisNeck MetastasisOccult Lymph Node MetastasisOccult Nodal MetastasisPrimary Tumor AssessmentPrimary Tumor Characterization
Abstract The aim of this study was to investigate the predictability of occult lymph node metastasis using maximum standardized uptake value (SUV max ) in the primary tumor on pre-treatment 18-fluorodeoxyglucose positron emission tomography FDG-PET in oral squamous cell carcinoma (OSCC) patients who were clinically node negative (cN0) before surgery. A retrospective analysis of all patients treated at the University Hospital Zurich from 2007 to 2016 for OSCC with available pre-therapeutic FDG-PET was performed. We assessed the correlation of SUV max of the primary tumors with the presence of occult nodal disease in the neck dissection specimen (pN+). The study included a total of 71 patients. In the nodal negative group (cN0/pN0), the median SUV max of primary tumors was 9.0 (interquartile range (IQR) 7.4–13.9), while it was 11.4 (IQR 9.9–15.7) in the occult metastatic group (cN0/pN+). The difference was statistically significant (independent samples median test, P = 0.037). In a multivariable model, the only independent predictor of occult metastatic disease for cN0 patients was a SUV max ≥ 9.5 ( P = 0.028). Further, primary tumors with SUV max ≥ 9.5 had a significantly higher risk of local recurrence (Log rank test, P = 0.020). In conclusion, we showed that higher SUV max (≥9.5) of the primary tumor is associated with higher occurrence of occult metastatic nodal disease and worse local survival. High SUV max of the primary tumor may encourage clinicians towards more aggressive treatment.
18
Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer
Anil D’Cruz, Richa Vaish, Neeti Madan Kapre et al. · New England Journal of Medicine · 2015 · 1.2K citations · Full text
Head and Neck Cancers, Version 2.2014
David G. Pfister, Sharon A. Spencer, David M. Brizel et al. · Journal of the National Comprehensive Cancer Network · 2014 · 281 citations · Full text
Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches
Sabrina Daniela da Silva, Michael Hier, Alex Mlynarek et al. · Frontiers in Pharmacology · 2012 · 135 citations · Full text
Medicine, Oncology, Pharmacotherapy +17